Viewing Study NCT00849667


Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2026-01-10 @ 2:30 PM
Study NCT ID: NCT00849667
Status: TERMINATED
Last Update Posted: 2022-12-30
First Post: 2009-02-13
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Sponsor: Morphotek
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ovarian cancer View
None relapsed ovarian cancer View
None Platinum-sensitive Ovarian Cancer View